Sanofi-Aventis: Lixisenatide aids blood-glucose control for Type 2 diabetics
PARIS An investigational treatment made by French drug maker Sanofi-Aventis showed “significant” improvement in blood-glucose control in patients with diabetes, according to results of a late-stage clinical trial presented at a scientific meeting.
Sanofi announced the first results of the phase-3 “GetGoal” clinical trial program of lixisenatide, a once-daily treatment for Type 2 diabetes. Results were presented at the European Association for the Study of Diabetes’ 46th annual meeting in Stockholm. The study, conducted over a 12-week period, involved 361 patients. The drug is a GLP-1 receptor agonist, belonging to the same class as Novo Nordisk’s Victoza (liraglutide) and Eli Lilly’s and Amylin Pharmaceuticals’ Byetta (exenatide).
“These results demonstrated lixisenatide as a once-daily GLP-1 agent with substantial A1C reduction and a pronounced effect on post-meal glucose control,” said study investigator and University of Rochester School of Medicine researcher John Gerich. “The pronounced effect on postprandial glucose control provides a rationale to investigate the combined effect of lixisenatide and long-acting insulins in patients with Type 2 diabetes.”
Walgreens offers pertussis immunizations in select Calif. stores
DEERFIELD, Ill. In response to the outbreak of pertussis, or “whooping cough,” in California, one drug store chain is offering pertussis vaccinations to its customers at more than 150 select stores throughout the state.
Walgreens said that its pharmacists in California can administer pertussis immunizations (tetanus/diphtheria/pertussis-Tdap vaccine) to anyone age 9 years or older with no appointment necessary. Officials from the Centers for Disease Control and Prevention and from the California Department of Public Health have recommended that Californians get vaccinated to prevent the spread of pertussis, which is said to be the worst epidemic the state has seen in the past 50 years.
“We share in the recommendations of state and federal health officials that the best thing people can do to keep themselves and their families healthy during this epidemic is to get vaccinated,” said Bill Hose, California market VP for Walgreens. “In addition to children, who are the most vulnerable, those who care for or are in contact with children should also be immunized, and we’re continuing to stress these important statewide recommendations to our patients, customers and the general public.”
FDA to review Actos for bladder cancer risk
SILVER SPRING, Md. The Food and Drug Administration said Friday it had begun a safety review of Takeda’s Type 2 diabetes treatment Actos (pioglitazone) after receiving five-year data from a 10-year study Takeda Pharmaceuticals North America is conducting on the drug showing that some patients taking it could be at risk for bladder cancer.
The results showed no overall association between taking Actos and risk of bladder cancer, but there was an increased risk among those taking the drug for the longest period of time and in those taking it at the highest cumulative dose. The FDA said it had not concluded that the drug increases patients’ bladder cancer risk.
Actos belongs to the same class as GlaxoSmithKline’s Avandia (rosiglitazone), which has come under fire lately after being linked to heart problems in patients, though the drug remains available in the United States.